Latest Articles
-
Phylo Adds Chugai as Second Major Japanese Pharma Customer
Phylo, Inc., a private San Francisco Bay Area AI research lab, announced on August 4 that Chugai Pharmaceutical Co., Ltd. will deploy Biomni Lab, Phylo’s agentic AI platform for biomedical research, across its drug discovery workflows. Chugai is not a startup taking a flyer on unproven software: it is a Tokyo Stock Exchange-listed pharmaceutical company,…
-
What Is Short Interest in Biotech Stocks? Reading a Key Sentiment Indicator
Ahead of a major biotech catalyst — a PDUFA date, a Phase 3 readout — one of the data points sophisticated investors check is short interest: how many shares of the stock are currently sold short, representing bets that the price will fall. Biotech stocks, with their binary catalysts and dramatic potential price swings, attract…
-
What Is Combination Therapy? Why Biotech Companies Pair Drugs Together
Look at the treatment regimen for almost any serious chronic or complex disease — HIV, tuberculosis, most advanced cancers, hepatitis C before it was cured — and you will find combination therapy: two or more drugs used together rather than a single agent alone. Combination therapy is one of the most consistently successful strategies in…
-
BWXT Sells Medical Isotopes Business to Nordic Capital for $800M
BWX Technologies, Inc. (NYSE: BWXT) announced on August 3 that it has entered a definitive agreement to sell its medical business, comprising BWXT Medical and Kinectrics’ stable medical isotopes unit, to Nordic Capital, a European private equity firm with a healthcare focus, in a transaction valued at up to $800 million. For investors, the deal…
-
Inside the inMIND Trial Data Behind Minjuvi’s New PBS Listing
Specialised Therapeutics (ST), a Singapore-headquartered specialty pharmaceutical company, announced in a press release on August 2 that Minjuvi (tafasitamab), used together with rituximab and lenalidomide, is now reimbursed under Australia’s Pharmaceutical Benefits Scheme (PBS) for adults with relapsed or refractory follicular lymphoma (R/R FL). For patients, the listing means government-subsidized access to a chemotherapy-free treatment…
-
What Is Real-World Evidence? How Data Outside Clinical Trials Is Reshaping FDA Decisions
For decades, the randomized controlled clinical trial was the only currency the FDA accepted as proof of a drug’s safety and efficacy. That is changing. Real-world evidence — data generated outside the traditional clinical trial setting, from sources like electronic health records, insurance claims, and patient registries — is increasingly being used to support FDA…
-
What Is the Difference Between a Drug Target and a Biomarker? A Guide for Biotech Investors
Two terms that appear in almost every substantive description of a biotech company’s drug development program are drug target and biomarker. They are related but distinct — and confusing the two is one of the most common sources of misinterpretation when retail investors read clinical trial descriptions, pipeline summaries, or drug mechanism explanations. Understanding the…
-
What Is Gene Therapy? How It Differs from Gene Editing and Why the Distinction Matters
Gene therapy and gene editing are two of the most transformative — and most frequently confused — technologies in modern biotechnology. Both operate at the level of DNA and both aim to treat disease by addressing its genetic roots. But they work in fundamentally different ways, and that difference has important implications for which diseases…
-
What Is Market Capitalization in Biotech? How to Read a Company’s Size and Stage
Market capitalization is one of the first numbers every investor learns, and one of the most frequently misinterpreted in the biotech context. In most industries, a company’s market cap reflects its current business — its revenue, profitability, and near-term growth trajectory. In biotech, especially for clinical-stage companies, market cap reflects something fundamentally different: the market’s…
-
What Is Off-Label Drug Use? The Practice Every Biotech Investor Should Understand
When the FDA approves a drug, it approves it for a specific indication — a defined patient population with a defined disease or condition. But once a drug is on the market, physicians are legally permitted to prescribe it for any use they believe is in their patient’s best interest, including uses not mentioned on…